Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma. (TV3/001/06)

Proposed period of release:
22/06/2006 to 31/01/2010

Name of the Institute(s) or Company(ies)
Oxford BioMedica UK Ltd., Medawar Centre,
Robert Robinson Avenue,
The Oxford Science Park,
OX4 4GA, United Kingdom;

3. Is the same GMO release planned elsewhere in the Community?
Germany; France; United Kingdom; Netherlands; Poland;

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Modified Vaccinia Ankara Virus ,Poxviridae, Vaccinia

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known